Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

caspofungin

caspofungin
  • Restricted Echinocandin Formulary
  • Restricted Cancidas --> restricted to ID use when micafungin is not a viable option.
  • Therapeutic Interchange
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Cancidas POWDER FOR INJECTION, INTRAVENOUS 50 mg, 70 mg    
VIEW MORE Echinocandins
CLASS
081416
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

caspofungin (Cancidas)

  • All formulations—( Candidemia, candidiasis, other candida infections) 70 mg loading dose followed by 50 mg or 30 mg daily

micafungin (Mycamine)

  • 100 mg powder for injection intravenous 100 mg Daily

caspofungin (Cancidas)

  • All formulations –(Esophageal Candidasis) 50 mg daily

micafungin (Mycamine)

  • all formulations – 150 mg Daily

Echinocandin Criteria For Use

Echinocandin Use in Pediatrics Formulary Evaluation

Reviewed: November 18, 2008 (Echinocandins in pediatrics) and January 26, 2010 and 28 March 2017 (Cancidas)

Last updated: Dec. 19, 2017
  • Formulary, Not Routinely Stocked: Cancidas --> 50 mg, 70 mg






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved